Skip to Main Content
Title
Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.
First Author
Greer, Joel W
Date of Pub
1999 Spring
Pages
55-62
Volume
20
Issue
3
Other Authors
Eggers, Paul W; Milam, Roger A
Abstract
In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges, and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and recent data for patients treated by in-center hemodialysis. In 1997 nearly all in-center hemodialysis patients received EPO regularly at an average cost per recipient of $6,245 per year for total allowed charges of $842.2 million per year. The study shows that policy changes may have both anticipated and unanticipated effects on medical practice.
Abstract Continued
N/A
MeSH
Drug Utilization Review : Anemia/drug therapy/etiology : Erythropoietin, Recombinant/administration & dosage/economics : Hemodialysis Units, Hospital/economics : Human : Insurance, Health, Reimbursement/statistics & numerical data : Insurance, Pharmaceutical Services/statistics & numerical data : Kidney Failure, Chronic/therapy : Medicare/statistics & numerical data : Treatment Outcome : United States : United States Health Care Financing Administration
NTIS Number
PB2000-102916